This year's Biomedical HIV Prevention Summit in Atlanta emphasized the importance of advancing prevention in the U.S. South, a region disproportionately impacted by HIV.
We’re focused on driving innovation in virology, oncology and immunology – and that includes investing in world-class science to change the way cancer is treated.
At Gilead, putting people first is central to all we do. That’s why we’re proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries.
As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered care models and innovative digital healthcare tools.
We’re proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help create a healthier world for all.
In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV.
Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.
Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.
We sat down with Dan Murphy and Dr. Jeffrey Lazarus to discuss the work that needs to be done to meet the United Nations' (U.N.) goal of ending the HIV epidemic by 2030 and to fully meet the needs of people living with HIV around the world.
Many of the communities who could most benefit from pre-exposure prophylaxis (PrEP) for HIV prevention haven’t been included in clinical trial design and execution over the years – but Gilead’s PURPOSE studies made their inclusion a primary goal.
As a way to support those impacted by Monday’s devastating earthquake in Türkiye and Syria, the Gilead Foundation is donating $1 million for on-the-ground relief efforts.
See, Vice President of Oncology Clinical Development at Gilead, took a moment to walk us through some of the new innovations in breast cancer and the work underway at Gilead Oncology, where the vision is to help bring more life to people with cancer.
As Gilead maps out its next decade, including plans for a new Research Center in Foster City, we talked with Flavius about Gilead’s history of innovation and plans for the future.
This year, she implemented a plan to remedy that – and with the support of a Gilead TRANScend grant, the Transinclusive Group opened a peer-run seven-bed housing program called CHOICES.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...